Dr. Samer Khatib, ISVER Board Member and Treasurer, presented research at the ARVO conference

The research deals with the development of a new, multidimensional drug based on inhibitory small molecules for the treatment of retinal and vascular diseases such as diabetic retinopathy, wet age-related macular degeneration, and venous occlusions.

We were able to demonstrate using cell cultures, tissues, and an animal model that our new compound, which works through a combined mechanism that is different from current treatments in clinical use, is highly effective in suppressing pathological new blood vessel growth. This development may form the basis for the development of new treatments for retinal diseases.